# Consolidated Financial Summary for the First Six Months Period of the Fiscal Year Ending March 31, 2021 [IFRS]

November 5, 2020

Listed Company:	YUKIGUNI MAITAKE CO., LTD.
Stock Exchange:	Tokyo Stock Exchange
Code Number:	1375
URL:	https://www.maitake.co.jp/
Representative:	Iwao Ashikaga, President and CEO, Representative Director
Contact:	Masahiro Komuro, Executive Officer (Chief Financial Officer)
Tel.:	+81-25-778-0162
Scheduled date to submit quarterly report:	November 6, 2020
Scheduled date of the start of dividends payment:	December 7, 2020
Supplementary material for quarterly financial results:	Yes
Briefing on quarterly financial results:	Yes (for analysts and institutional investors)

1. Consolidated Financial Results for the First Six Months Period of the Fiscal Year Ending March 31, 2021 (from April 1, 2020 to September 30, 2020)

(1) Consolidated Operating Results (Cumulative)

(Millions of yen with fractional amounts discarded) (Percentages indicate year-on-year changes)

(1) Consolidated Operating Re	suits (Cumulati	100)	(Fercentages indicate year-on-year change					ai changes)
	Total income		Operating profit		Profit before tax		Profit	t
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
First six months of the year ending March 31, 2021	22,655	6.1	3,280	19.2	3,019	22.6	1,959	22.6
First six months of the year ended March 31, 2020	21,360	_	2,753	_	2,462	_	1,598	_

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
	Millions of yen	%	Millions of yen	%	Yen	Yen
First six months of the year ending March 31, 2021	1,966	22.9	1,972	24.0	49.35	49.32
First six months of the year ended March 31, 2020	1,600	_	1,590	_	40.17	40.15

(Note) Effective July 30, 2020, YUKIGUNI MAITAKE CO., LTD. (hereinafter "the Company") split the shares of its common stock on a 100-for-1 basis. Basic earnings per share and diluted earnings per share have been restated, as appropriate, on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

(Reference)

	Adjusted operating profit		Adjusted EBITDA		Adjusted profit		Adjusted basic earnings per share	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen	%
First six months of the year ending March 31, 2021	3,544	24.1	4,509	21.8	2,221	29.1	55.75	29.1
First six months of the year ended March 31, 2020	2,856	_	3,703	_	1,720	_	43.18	_

#### (2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
	Millions of yen	Millions of yen	Millions of yen	%
As of September 30, 2020	36,857	6,874	6,880	18.7
As of March 31, 2020	35,199	4,901	4,899	13.9

2. Dividends

		Dividend per share							
	End of 1st quarter	End of 2nd quarter	End of 3rd quarter	Year end	Annual Total				
	Yen	Yen	Yen	Yen	Yen				
Year ended March 31, 2020	_	0.00	4,230.00	0.00	4,230.00				
Year ending March 31, 2021	_	14.00							
Year ending March 31, 2021(forecast)			_	28.00	42.00				

(Notes) 1. Revisions from dividends forecasts announced most recently: None

2. Effective July 30, 2020, the Company split the shares of its common stock on a 100-for-1 basis. The amount of dividend per share approved for the fiscal year ended March 31, 2020 has not been adjusted to reflect such share split.

# 3. Forecast of Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 (from April 1, 2020 to March 31, 2021)

									(Percentages indicate year-on-year changes)			
	Total income		Operating p	rofit	Profit before	e tax	Profit		Profit attribu owners of p		Basic earnings per share	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen	
Full year	52,678	3.8	8,324	24.4	7,783	17.1	5,099	17.4	5,099	17.3	127.96	

(Notes) 1. Revisions from financial results forecasts announced most recently: None

<sup>2.</sup> Basic earnings per share have been restated, as appropriate, to reflect a 100-for-1 stock split effect on July 30, 2020.

(Reference)
-------------

	Adjusted opera	ting profit	Adjusted EE	BITDA	Adjusted p	orofit	Adjusted basic earnings per share		
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen	%	
Full year	8,618	24.9	10,453	20.5	5,466	27.6	137.17	27.6	

\* Notes

(1) Changes in significant subsidiaries during the period (changes in specific subsidiaries accompanied by a change in the scope of consolidation): None

(2) Changes in accounting policies and changes of accounting assumptions

(i)	Changes in acc	counting polici	es as required by IFRS:	None
(-)	entanges in aet	pound point		1.00110

- (ii) Changes in accounting policies other than (i): None
- (iii) Changes in accounting assumptions: None

(3) Number of shares outstanding (common stock)

(i) Number of shares issued (including treasury s	stock) at the end of the term:
As of September 30, 2020	39,850,000 shares
As of March 31, 2020	39,850,000 shares
(ii) Number of shares of treasury stock at the end	of the term:
As of September 30, 2020	- shares
As of March 31, 2020	- shares
(iii) Average number of shares during the period	
Six months ended September 30, 2020	39,850,000 shares
Six months ended September 30, 2019	39,850,000 shares

(Note) Effective July 30, 2020, the Company split the shares of its common stock on a 100-for-1 basis. The number of shares issued has been restated, as appropriate, to reflect a 100-for-1 stock split effect on July 30, 2020.

\* Summaries of quarterly consolidated financial statements are not subject to reviews conducted by certified public accountants or audit firms.

\* Notes regarding proper use of forecasts of financial results, and other special comments

(Caution concerning forward-looking statements)

The forward-looking statements, such as forecasts of financial results, included in this document are based on information available to the management as of the date of the document and certain assumptions that the management considers reasonable. The Company does not promise that forecasts will be achieved. Actual results may differ significantly due to a range of factors.

(Other special comments)

- (1) The Company and its consolidated subsidiaries (together, "the Group") apply the International Financial Reporting Standards (hereinafter "IFRS") to and after the fiscal year ended March 31, 2020.
- (2) Adjusted operating profit = Operating profit + Management fee + Listing-related expenses
- (3) Adjusted EBITDA = Adjusted operating profit + Depreciation + Amortization
- (4) Adjusted profit for the period or year = Profit for the period or year + Management fee + Listing-related expenses + Refinancing-related gains/losses + Tax adjustments
- (5) In (4), "Listing-related expenses" are temporary costs including listing preparation advisory costs, costs related to building an organizational structure for listing, costs related to the introduction of IFRS and timely disclosure system for listing, real estate registration costs associated with a merger, etc. "Refinancing-related gains / losses" are advisory expenses that were temporarily incurred in connection with refinancing carried out after the Company was closed to the public. These expenses are offset by temporary gains that were incurred due to the decline in contract interest rates associated with the refinancing and the increase in interest expense during the remaining contract period that occurs in conjunction with the refinancing.
- (6) Adjusted basic earnings per share = Adjusted profit for the period or year/Average number of shares during the period or year
- (7) Adjusted operating profit, Adjusted EBITDA, Adjusted profit for the period or year and Adjusted basic earnings per share are not indicators defined by IFRS, but the Group assumes these indicators are useful for investors to evaluate the Group's performance. These financial indicators exclude some expenses and non-recurring gains / losses that are not expected to occur after listing. Adjusted Operating Profit, Adjusted EBITDA, Adjusted profit for the period or year and Adjusted basic earnings per share should not be considered as indicators to replace the other indicators shown in accordance with IFRS because they do not include some of the items that affect the profit for the period, so they are subject to significant restrictions as means of analysis. Adjusted Operating Profit, Adjusted EBITDA, Adjusted profit for the period or year and Adjusted basic earnings per share disclosed by the Group may be less useful in comparison with the same or similar indicators of other competitors because they are calculated according to a different method from that of such other companies.

(How to obtain supplementary financial results briefing materials and financial results briefing details)

We plan to hold a live streaming of the financial results briefing for institutional investors and analysts on Monday, November 9, 2020. The financial results briefing presentation materials are posted on our website from November 5, 2020.

1.	Qualitative Information for the First Six-Month Period of the Fiscal Year Ending March 31, 20212
	(1) Analysis of Operating Results 2
	(2) Analysis of Financial Position
	(3) Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results4
2.	Summarized Quarterly Consolidated Financial Statements and Significant Notes5
	(1) Summarized Quarterly Consolidated Statements of Financial Position
	(2) Summarized Quarterly Consolidated Statements of Income and Comprehensive Income
	(3) Summarized Quarterly Consolidated Statement of Changes in Equity
	(4) Summarized Quarterly Consolidated Statements of Cash Flows10
	(5) Notes to Summarized Quarterly Consolidated Financial Statements11
	(Going Concern Assumptions)11
	(Segment Information)11
	(Earnings per Share)12
	(Significant Subsequent Events)

- 1. Qualitative Information for the First Six-Month Period of the Fiscal Year Ending March 31, 2021
- (1) Analysis of Operating Results

The domestic economy during the first six months of the current consolidated fiscal year (April 1, 2020 to September 30, 2020) remained extremely sluggish due to the effects of the novel coronavirus disease (COVID-19). Although government-led policies have facilitated some economic recovery and domestic consumer sentiment has partially improved, the outlook remains uncertain.

In the domestic mushroom market, demand for mushrooms increased, and sales were strong due to (1) more cooking opportunities at home avoiding going out, (2) growing demand for functional foods attributable to heightened health awareness, and (3) soaring vegetable prices caused by poor growth under unseasonable weather in early summer.

In such an environment, the Group continued to promote the development and appeal of mushroom functionality focusing on maitake, under our fundamental policy of our medium-term business plan, "Establishing a foundation as a comprehensive manufacturer of premium mushrooms." By doing so, we have developed a position as a year-round foodstuff rather than seasonal one, and at the same time, we have developed our business to contribute to the realization of a healthy society by providing safe and secure products to our customers.

Total income for the first six months of the current consolidated fiscal year was ¥22,655 million (+6.1% year-onyear), of which revenue was ¥14,997 million (+4.3% year-on-year). Revenue increased due to the steady performance of our mushroom business, including an increase in sales from Mitsukura Norin Co., Ltd., which was acquired in October 2019. Gross profit was ¥7,383 million (+12.0% year on year) due to a decrease in the cost of sales ratio, a decrease in utility costs, quality improvement, and improvement in production efficiency. Selling, general and administrative expenses increased to ¥3,957 million (+1.7% year on year) due to an increase in freight costs and sales commissions associated with increased revenue.

As a result of the above, operating profit for the first six months of the current consolidated fiscal year was \$3,280 million (+19.2% year on year) and profit attributable to owners of parent was \$1,966 million (+22.9% year on year). In the first six months of the current consolidated fiscal year, gains arising from changes in fair value related to the application of IFRS Agriculture Accounting (IAS 41) were included in income of \$7,657 million and cost of sales of \$6,846 million.

		(N	fillions of yen)
	Six months ended September 30, 2019	Six months ended September 30, 2020	% Change year on year
Revenue	14,377	14,997	4.3
Gains arising from changes in fair value	6,982	7,657	9.7
Total income	21,360	22,655	6.1
Operating profit	2,753	3,280	19.2
Profit before tax	2,462	3,019	22.6
Profit (attributable to owners of parent)	1,600	1,966	22.9

[Business results for the six months ended September 30, 2020]

The status of revenue by business segment during the first six months of the current consolidated fiscal year is as follows.

[Mushroom business]

1) Maitake

On top of promoting the functionality of maitake, we have developed a position as a year-round foodstuff rather than a seasonal one and also developed a product strategy utilizing extensive product lineup through gaining high praise from customers on the balance of *umami*, flavor, and good texture. In the first six months of the current consolidated fiscal year, the unit price was lower than that of the same period of the previous year, but the sales volume remained strong. As a result, revenue from the maitake business segment was \$8,402 million (+1.6% year-on-year).

# 2) Eringi

In addition to achieving stable supply by improving production quality, we are expanding our product lineup by launching strategic products that meet consumer needs, and both sales volume and unit price are higher than those of the same period of the previous year. As a result, revenue from the Eringi business segment was \$1,694 million (+10.5% year on year).

# 3) Buna-shimeji

By paying close attention to the fruit and vegetable market and market trends and launching products in line with the balance between supply and demand, the unit sales price remained higher than that of the same period of the previous year. As a result, revenue from the Buna-shimeji business segment was 2,960 million (+6.5% year on year).

# 4) Other mushrooms

Mitsukura Norin Co., Ltd., which was acquired in October 2019, contributed to the increase in revenue. As a result, revenue from the other mushrooms business segment was \$1,683 million (+128.0% year on year).

# [Other]

Revenue from the "other" business segment was ¥255 million (-75.7% year on year) due to the closures of the cut vegetables and natto business in February 2020.

a .....

Revenue by business segment is as follows.

				(Millions of yen)
		Six months ended September 30, 2019	Six months ended September 30, 2020	% Change year on year
Mushroom business		13,325	14,741	10.6
	Maitake	8,273	8,402	1.6
	Eringi	1,533	1,694	10.5
	Buna-shimeji	2,780	2,960	6.5
	Other mushrooms	738	1,683	128.0
0	ther	1,052	255	-75.7
Total Revenue		14,377	14,997	4.3

#### (2) Analysis of Financial Position

# 1) Financial position

[Assets]

Total assets at the end of the second quarter of the current consolidated fiscal year (as of September 30, 2020) were ¥36,857 million (+¥1,658 million from the end of the previous consolidated fiscal year). Current assets were ¥11,492 million (+¥446 million year on year). This was mainly due to a decrease of ¥952 million in cash and cash equivalents, an increase of ¥950 million in biological assets, ¥298 million in trade and other receivables, and ¥184 million in inventories. Non-current assets were ¥25,365 million (+¥1,211 million year on year). This was mainly due to an increase of ¥1,356 million in property, plant and equipment associated with

facility expansion and renewal related to increased production of maitake.

# [Liabilities]

Total liabilities at the end of the second quarter of the current consolidated fiscal year were \$29,982 million (-\$315 million). Current liabilities were \$7,424 million (+\$143 million year on year). This was mainly due to a decrease of \$475 million in accrued income taxes and decrease of \$461 million in other liabilities, while trade and other payables increased by \$814 million, and employee benefits liabilities increased by \$179 million. Non-current liabilities were \$22,558 million (-\$459 million). This was mainly due to a decrease in borrowings of \$389 million.

# [Equity]

Total equity at the end of the second quarter of the current consolidated fiscal year was \$6,874 million (+\$1,973 million year on year). This was mainly due to the recording of a profit of \$1,959 million.

# 2) Cash flows

The balance of cash and cash equivalents at the end of the second quarter of the current consolidated fiscal year decreased by ¥952 million from the end of the previous consolidated fiscal year to ¥3,508 million. The status of each cash flow and their factors are as follows:

# [Net cash flows from operating activities]

The amount of funds acquired as a result of operating activities was \$1,292 million (the amount used was \$1,320 million in the same period of the previous year). This was mainly due to the recording of profit before tax of \$3,019 million, depreciation and amortization of \$964 million, an increase in inventories \$184 million due to strong sales, and an increase in biological assets of \$950 million. On the other hand, there was a income tax payment of \$1,682 million.

#### [Net cash flows from investing activities]

The funds used as a result of investing activities amounted to \$1,652 million (the amount used was \$389 million in the same period of the previous year). This was mainly due to the expenditure of \$1,639 million for the purchase of property, plant and equipment associated with the expansion and renewal of facilities related to the increase in production of maitake. In addition, in the same period of the previous year, income from the sale of land owned by the Company in Shiga Prefecture was also a factor of fluctuation.

#### [Net cash flows from financing activities]

Funds used as a result of financing activities amounted to \$592 million (the amount used was \$1,096 million in the same period of the previous year). This was mainly due to the repayments of long-term borrowings of \$481 million. In the same period of the previous year, the advance repayment of long-term borrowings was also a factor in the fluctuation.

# (3) Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results Regarding the consolidated financial results forecast, there is no change in the full-year consolidated financial results forecast announced in "Notice of Our Financial Results, etc. Accompanying Listing on the First Section of the Tokyo Stock Exchange" on September 17, 2020. The financial results forecast is based on the information available at this time, and the actual financial results may differ due to various factors.

#### 2. Summarized Quarterly Consolidated Financial Statements and Significant Notes

# (1) Summarized Quarterly Consolidated Statements of Financial Position

(Millions of yen) As of March 31, 2020 As of September 30, 2020 Assets Current assets 4,461 Cash and cash equivalents 3,508 Trade and other receivables 2,141 2,439 Inventories 1,292 1,476 **Biological** assets 3,019 3,970 Other financial assets 0 Other current assets 131 97 Total current assets 11,045 11,492 Non-current assets Property, plant and equipment 16,710 18,066 Investment property 364 316 Goodwill and intangible assets 5,320 5,311 Right-of-use assets 597 523 Retirement benefit asset 310 301 Other financial assets 145 152 Deferred tax assets 646 641 Other non-current assets 50 58 Total non-current assets 24,153 25,365 35,199 36,857 Total assets

		(ivinitions of year
	As of March 31, 2020	As of September 30, 2020
Liabilities		
Current liabilities		
Trade and other payables	2,390	3,205
Accrued income taxes	1,539	1,064
Employee benefit liabilities	1,577	1,757
Current portion of long-term borrowings	942	1,037
Lease liabilities	196	199
Other financial liabilities	26	15
Other current liabilities	605	144
Total current liabilities	7,280	7,424
Non-current liabilities		
Borrowings	22,438	22,048
Lease liabilities	483	416
Defend tax liabilities	11	11
Provisions	17	17
Other financial liabilities	55	61
Other non-current liabilities	10	2
Total non-current liabilities	23,017	22,558
Total liabilities	30,297	29,982
Equity		
Share capital	100	100
Capital surplus	(6,046)	(6,046)
Retained earnings	10,828	12,795
Other components of equity	17	31
Total equity attributable to owners of parent	4,899	6,880
Non-controlling interests	1	(5)
Total equity	4,901	6,874
Total liabilities and equity	35,199	36,857

# (2) Summarized Quarterly Consolidated Statements of Income and Comprehensive Income

(Summarized Quarterly Consolidated Statements of Income)

		(Millions of year
	Six months ended September 30, 2019	Six months ended September 30, 2020
Income		
Revenue	14,377	14,997
Gains arising from changes in fair value	6,982	7,657
Total income	21,360	22,655
Cost of sales (*1)	14,767	15,272
Gross profit	6,592	7,383
Selling, general and administrative expenses	3,890	3,957
Other income	220	27
Other expenses	169	171
Operating profit	2,753	3,280
Finance income	21	0
Finance expenses	312	262
Profit before tax	2,462	3,019
Income tax expense	863	1,059
Profit	1,598	1,959
Profit attributable to		
Owners of parent	1,600	1,966
Non-controlling interests	(1)	(6)
Earnings per share (Yen)		
Basic earnings per share (Yen)	40.17	49.35
Diluted earnings per share (Yen)	40.15	49.32

Management believes that the information of "material costs, labor costs, etc." facilitates comparison between the Group and other companies in the same industry by users of financial statements. Therefore, we disclose the information voluntarily as a note in the summarized quarterly consolidated statements of income. "Material costs, labor costs, etc." are the production costs of fresh mushrooms and purchasing costs of other goods sold by the Group, excluding the gains from fluctuations in fair value recognized under IAS 41 "Agriculture".

(*1) Components of cost of sales				
Material costs, labor costs, etc.	8,663	8,425		
Gains arising from changes in fair value	6,104	6,846		
Total	14,767	15,272		

# (Summarized Quarterly Consolidated Statements of Comprehensive Income)

	Six months ended September 30, 2019	Six months ended September 30, 2020
Profit	1,598	1,959
Other comprehensive income (after tax effect deduction)		
Items that will not be reclassified to profit or loss		
Net change in equity instruments measured at fair value	(9)	12
through other comprehensive income	(8)	12
Total of items that will not be reclassified to profit or loss	(8)	12
Total of other comprehensive income (after tax effect deduction)	(8)	12
Comprehensive income	1,590	1,972
Comprehensive income attributable to		
Owners of parent	1,592	1,978
Non-controlling interests	(1)	(6)

# (3) Summarized Quarterly Consolidated Statement of Changes in Equity

Sin monais chece Septeme	<i>,</i> , , , , , , , , , , , , , , , , , ,	1 /	1	,	,	(Milli	ons of yen)
	Share capital	Capital surplus	Retained earnings	Other components of equity	Equity attributable to owners of parent	Non- controlling interests	Total equity
Balance as of April 1, 2019	100	(4,360)	6,524	44	2,308	3	2,312
Profit	-	-	1,600	-	1,600	(1)	1,598
Other comprehensive income	-	-	-	(8)	(8)	-	(8)
Total comprehensive income	-	-	1,600	(8)	1,592	(1)	1,590
Transfer from other components of equity to retained earnings Other	-	-	3	(3)	- 2	-	- 2
Total transactions with owners of parent	_	-	3	(1)	2		2
Balance as of September 30, 2019	100	(4,360)	8,128	34	3,902	1	3,904

# Six months ended September 30, 2019 (From April 1, 2019 to September 30, 2019)

Six months ended September 30, 2020 (From April 1, 2020 to September 30, 2020)

						(Milli	ons of yen)
	Share capital	Capital surplus	Retained earnings	Other components of equity	Equity attributable to owners of parent	Non- controlling interests	Total equity
Balance as of April 1, 2020	100	(6,046)	10,828	17	4,899	1	4,901
Profit	-	-	1,966	-	1,966	(6)	1,959
Other comprehensive income	-	-	-	12	12	-	12
Total comprehensive income	-	-	1,966	12	1,978	(6)	1,972
Transfer from other components of equity to retained earnings	-	-	-	-	-	-	-
Other	-	-	-	1	1	-	1
Total transactions with owners of parent	-	-	-	1	1	-	1
Balance as of September 30, 2020	100	(6,046)	12,795	31	6,880	(5)	6,874

	Six months ended	Six months ended
	September 30, 2019	September 30, 2020
Cash flows from operating activities		
Profit before tax	2,462	3,019
Depreciation and amortization	847	964
Interest expense	261	252
Commission for syndicate loan	46	9
Loss (gain) on sale of fixed assets	(197)	(1)
Loss on disposal of fixed assets	104	72
Decrease (increase) in trade and other receivables	407	(298)
Decrease (increase) in inventories	(613)	(184)
Decrease (increase) in biological assets	(763)	(950)
Increase (decrease) in trade and other payables	(1,537)	(17)
Decrease (increase) in retirement benefit asset	13	9
Increase (decrease) in employee benefit liabilities	(695)	179
Other	(632)	(143)
Subtotal	(296)	2,911
Interest paid	(144)	(79)
Commission for syndicate loan paid	(16)	(7)
Income tax paid	(1,204)	(1,682)
Income tax refund	342	149
Net cash inflow (outflow) from operating activities	(1,320)	1,292
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,038)	(1,639)
Proceeds from sale of property, plant and equipment	702	3
Purchase of intangible assets	(18)	(3)
Other	(35)	(12)
Net cash flow (outflow) from investing activities	(389)	(1,652)
Cash flows from financing activities		
Repayments of long-term borrowings	(992)	(481)
Repayments of lease liabilities	(103)	(111)
Other	(1)	(0)
Net cash flow (outflow) from financing activities	(1,096)	(592)
Effect of exchange rate changes on cash and cash		
equivalents	(0)	(0)
Net increase (decrease) in cash and cash equivalents	(2,807)	(952)
Cash and cash equivalents at the beginning of the period	6,617	4,461
Cash and cash equivalents at the end of the period	3,810	3,508

#### (5) Notes to Summarized Quarterly Consolidated Financial Statements

# (Going Concern Assumptions) Not applicable.

#### (Segment Information)

(1) Reportable segments

The Group's reportable segments are components of the Group for which separate financial information is available and regular evaluation by the Board of Directors, chief operating decision maker, is being performed in order to make decisions about resources to be allocated and to assess its performance.

The mushroom business is listed as a reporting segment as the Group has a comprehensive strategy for products and services and is expanding its business activities. "Other" includes businesses that are not included in the reportable segment.

The Group aggregates maitake business, eringi business, buna-shimeji business, etc. as a reportable segment, "mushroom business," in terms of similarity of economic characteristics such as revenue trends, and the following features are all similar in this segment: (a) the nature of products and services, (b) the nature of the production processes, (c) the type of customers of the products and the services, (d) the method used to deliver the products or provide the services, and (e) the nature of regulatory environment.

Description of the reportable segment is as follows:

	Description of business
Mushroom business	Production and sales of maitake, eringi, buna-shimeji and other mushrooms

(2) Reportable segments information

The accounting methods of reportable business segments are the same as the Group's accounting policies. Figures reported as segment profit are based on the operating profit reported in the summarized quarterly consolidated statements of income. Revenues from intersegment transactions are based on the current market prices.

A C 111

c

Six months ended September 30, 2019 (From April 1, 2019 to September 30, 2019)

				(Mil	lions of yen)
	Mushroom business	Others	Total	Adjustment items (*)	Per consolidated financial statements
Revenue					
Revenue from external customers	13,325	1,052	14,377	-	14,377
Intersegment revenue	-	1	1	(1)	-
Total revenue	13,325	1,053	14,379	(1)	14,377
Segment profit (loss)	2,474	87	2,562	191	2,753
Finance income					21
Finance expenses					312
Profit before tax					2,462

(Note) Adjustment items include corporate expenses that are not allocated to each business segment.

(Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*)	Per consolidated financial statements
Revenue					
Revenue from external customers	14,741	255	14,997	-	14,997
Intersegment revenue	-	19	19	(19)	-
Total revenue	14,741	275	15,017	(19)	14,997
Segment profit (loss)	3,319	33	3,353	(72)	3,280
Finance income					0
Finance expenses					262
Profit before tax					3,019

(Note) Adjustment items include corporate expenses that are not allocated to each business segment.

# (Earnings per Share)

Calculation of basic earnings per share and diluted earnings per share are described below.

	(Unit)	Six months ended September 30, 2019	Six months ended September 30, 2020
Basic earnings per share			
Profit attributable to owners of parent	(Millions of yen)	1,600	1,966
Profit not attributable to common shareholders of the Company	(Millions of yen)	-	-
Profit used for calculation of basic interim earnings per share	(Millions of yen)	1,600	1,966
Average number of common shares during the period	(Thousand shares)	39,850	39,850
Basic earnings per share	(Yen)	40.17	49.35
Diluted earnings per share			
Profit used for calculation of basic interim earnings per share	(Millions of yen)	1,600	1,966
Adjustment	(Millions of yen)	-	-
Profit used for calculation of diluted interim earnings per share	(Millions of yen)	1,600	1,966
Average number of common shares during the period	(Thousand shares)	39,850	39,850
Increase of shares due to stock acquisition rights	(Thousand shares)	16	21
Average number of common shares during the period after dilution	(Thousand shares)	39,866	39,871
Diluted earnings per share	(Yen)	40.15	49.32

(Note) Effective July 30, 2020, the Company split the shares of its common stock on a 100-for-1 basis. Basic earnings per share and diluted earnings per share have been restated, as appropriate, on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

(Significant Subsequent Events)

No items to report.